ÌÇÐÄvlog

[Skip to Navigation]
Sign In

Year

Day

September 26, 2024
Original Investigation

Oral Microbiome and Subsequent Risk of Head and Neck Squamous Cell Cancer

Abstract Full Text
JAMA Oncol. Published online September 26, 2024. doi:10.1001/jamaoncol.2024.4006

This prospective case-control study nested in 3 large, well-established, prospective US cohorts examines whether the oral bacterial and fungal microbiome is associated with subsequent head and neck squamous cell cancer risk.

Complete Response to Locoregional Therapy Plus Immunotherapy for Hepatocellular Carcinoma

Abstract Full Text
JAMA Oncol. Published online September 26, 2024. doi:10.1001/jamaoncol.2024.4085

This cohort study examines 3-year survival among patients with hepatocellular carcinoma placed on a watch-and-wait protocol after achieving complete remission with combined locoregional therapy and immunotherapy.

JAMA Oncology Clinical Challenge

Recurrent Fevers in a Patient With Splenomegaly

Abstract Full Text
has active quiz
JAMA Oncol. Published online September 26, 2024. doi:10.1001/jamaoncol.2024.4029

A 36-year-old man presented with 10 weeks of recurrent fevers, malaise, night sweats, unintentional weight loss, and dyspnea. What is your diagnosis?

Viewpoint

How Can Guidelines Give Clearer Guidance on Prostate Cancer Screening?

Abstract Full Text
JAMA Oncol. Published online September 26, 2024. doi:10.1001/jamaoncol.2024.3909

This Viewpoint explores how guideline groups can come together to agree on a framework that produces clear and unified recommendations.

Poetry and Oncology

Heartbreaker

Abstract Full Text
JAMA Oncol. Published online September 26, 2024. doi:10.1001/jamaoncol.2024.3912
Comment & Response

Meta-Analysis Methods for Neoadjuvant Chemoimmunotherapy for Non–Small Cell Lung Cancer

Abstract Full Text
JAMA Oncol. Published online September 26, 2024. doi:10.1001/jamaoncol.2024.4211

Meta-Analysis Methods for Neoadjuvant Chemoimmunotherapy for Non–Small Cell Lung Cancer—Reply

Abstract Full Text
JAMA Oncol. Published online September 26, 2024. doi:10.1001/jamaoncol.2024.4214
September 19, 2024
Original Investigation

Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer: A Nonrandomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. Published online September 19, 2024. doi:10.1001/jamaoncol.2024.3891

This nonrandomized clinical trial examines the safety and efficacy of guanylate cyclase-C (GCC) chimeric antigen receptor T-cell therapy in patients with metastatic colorectal cancer.

Brief Report

Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. Published online September 19, 2024. doi:10.1001/jamaoncol.2024.3900

This nonrandomized clinical trial evaluates the safety, pharmacokinetics, and preliminary efficacy of rogaratinib in combination with the programmed cell death 1 ligand 1 inhibitor atezolizumab in cisplatin-ineligible patients with FGFR messenger RNA–positive, locally advanced/metastatic urothelial cancer.

Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non–Small Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. Published online September 19, 2024. doi:10.1001/jamaoncol.2024.3089

This randomized clinical trial examines whether stereotactic body radiotherapy improves local control compared with hypofractionated conventional radiotherapy.

Research Letter

Transperineal vs Transrectal Prostate Biopsy—The PREVENT Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. Published online September 19, 2024. doi:10.1001/jamaoncol.2024.4000

This randomized clinical trial compares the effect of transperineal vs transrectal prostate biopsy on infection rates after biopsy.

Viewpoint

Standardized Definitions for Efficacy End Points for Adjuvant Trials—The Updated STEEP Criteria

Abstract Full Text
JAMA Oncol. Published online September 19, 2024. doi:10.1001/jamaoncol.2024.3888

This Viewpoint discusses how the inclusion or exclusion of certain events in the standardization of clinical trial end points can affect the interpretation of results.

Invited Commentary

Stereotactic Body Radiotherapy for Medically Inoperable Early-Stage Non–Small Cell Lung Cancer

Abstract Full Text
JAMA Oncol. Published online September 19, 2024. doi:10.1001/jamaoncol.2024.2905
September 12, 2024
Original Investigation

Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival

Abstract Full Text
JAMA Oncol. Published online September 12, 2024. doi:10.1001/jamaoncol.2024.3666

This single-center cohort study examines the association of molecular, socioeconomic, and clinical covariates with race and ethnicity disparities in overall survival among patients with colorectal cancer.

Brief Report

Cervical Cancer Incidence in the US-Affiliated Pacific Islands

Abstract Full Text
JAMA Oncol. Published online September 12, 2024. doi:10.1001/jamaoncol.2024.3675

This cross-sectional study examines the population-based incidence of cervical cancer in 6 US-Affiliated Pacific Islands from 2007 to 2020.

Research Letter

Radiation-Associated Secondary Cancer in Patients With Breast Cancer Harboring TP53 Germline Variants

Abstract Full Text
JAMA Oncol. Published online September 12, 2024. doi:10.1001/jamaoncol.2024.3683

This cohort study examines the risk of radiation-associated sarcoma in patients with breast cancer harboring germline TP53 variants.

Review

Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer: A Review

Abstract Full Text
has active quiz
JAMA Oncol. Published online September 12, 2024. doi:10.1001/jamaoncol.2024.3679

This review analyzes the heterogeneity of residual disease after neoadjuvant systemic therapy in patients with breast cancer.

Viewpoint

Accrual to Radiotherapy Trials in the US—Pitfalls and Potential Solutions

Abstract Full Text
JAMA Oncol. Published online September 12, 2024. doi:10.1001/jamaoncol.2024.3663

This Viewpoint discusses accrual difficulties of radiotherapy cooperative group trials and proposes solutions.

Invited Commentary

Contributions to Colorectal Cancer Disparities

Abstract Full Text
JAMA Oncol. Published online September 12, 2024. doi:10.1001/jamaoncol.2024.3516
September 5, 2024
Original Investigation

Inpatient Care and Outcomes Among People With Cancer Experiencing Homelessness

Abstract Full Text
JAMA Oncol. Published online September 5, 2024. doi:10.1001/jamaoncol.2024.3645

This cross-sectional study of data from the Agency for Healthcare Research and Quality’s Healthcare Cost and Utilization Project National Inpatient Sample investigates whether housing status is associated with the receipt of inpatient care and outcomes among hospitalized adults with cancer who are experiencing homelessness.

Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer

Abstract Full Text
has audio
JAMA Oncol. Published online September 5, 2024. doi:10.1001/jamaoncol.2024.3651

This cross-sectional study examines clinicogenomic features of Lynch syndrome and characterizes responses to immune checkpoint blockade therapy.

Research Letter

Frequency of ERBB2-Low Expression in Endometrial Cancer

Abstract Full Text
open access
JAMA Oncol. Published online September 5, 2024. doi:10.1001/jamaoncol.2024.3660

This study reanalyzes epidermal growth factor receptor 2 (ERBB2) data from a previous study to characterize patient subgroups with ERBB2-low tumors.

Cancer Care Chronicles

Persons With Cancer Rather Than Cancer Patients—Semantics Matter

Abstract Full Text
JAMA Oncol. Published online September 5, 2024. doi:10.1001/jamaoncol.2024.3642

This essay describes a physician’s shift to patient-focused language in treatment of patients with cancer.

×